

MacLean Michael F
Form 4
August 03, 2010

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
MacLean Michael F

2. Issuer Name and Ticker or Trading Symbol
BIOGEN IDEC INC. [BIIB]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
BIOGEN IDEC INC., 133 BOSTON POST ROAD

3. Date of Earliest Transaction (Month/Day/Year)
08/02/2010

____ Director
 Officer (give title below) _____ 10% Owner
_____ Other (specify below)
SVP, Chief Accounting Officer

(Street)
WESTON, MA 02493

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	08/02/2010		S ⁽¹⁾		\$ 56.8669 (3) (4)	D	
Common Stock	08/02/2010		S ⁽¹⁾		\$ 56.8458 (3) (5)	D	
Common Stock	08/02/2010		S ⁽¹⁾		\$ 56.8447 (3) (6)	D	
Common Stock	08/02/2010		S ⁽¹⁾		\$ 56.8677	D	

Edgar Filing: MacLean Michael F - Form 4

					(3) (7)			
Common Stock	08/02/2010	S ⁽¹⁾	2,047	D	\$ 56.8304	14,422.4773	D	(3) (8)
Common Stock	08/02/2010	S ⁽¹⁾	582	D	\$ 56.9107	13,840.4773	D	(3) (9)
Common Stock	08/02/2010	S ⁽¹⁾	2,206	D	\$ 56.8439	11,634.4773	D	(3) (10)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Beneficially (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MacLean Michael F BIOGEN IDEC INC. 133 BOSTON POST ROAD WESTON, MA 02493			SVP, Chief Accounting Officer	

Signatures

Robert A. Licht, Attorney in Fact for Michael F.
MacLean

08/03/2010

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) Includes 534,5306 shares acquired under the Biogen Idec Inc. employee stock purchase plan on 3/31/2010.
- (3) Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- (4) This represents the weighted average price for shares sold at a range between \$56.46 (low) and \$57.17 (high).
- (5) This represents the weighted average price for shares sold at a range between \$56.55 (low) and \$57.12 (high).
- (6) This represents the weighted average price for shares sold at a range between \$56.52 (low) and \$57.27 (high).
- (7) This represents the weighted average price for shares sold at a range between \$56.54 (low) and \$57.27 (high).
- (8) This represents the weighted average price for shares sold at a range between \$56.52 (low) and \$57.21 (high).
- (9) This represents the weighted average price for shares sold at a range between \$56.63 (low) and \$57.18 (high).
- (10) This represents the weighted average price for shares sold at a range between \$56.45 (low) and \$57.19 (high).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.